Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC.CERO · Entity 8622 | Director · Chief Technical Officer | March 25, 2024 | March 27, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CERO THERAPEUTICS HOLDINGS, INC.
Report date March 25, 2024 · Filed March 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2034-03-24 | Direct | 856,671 |
Reported balance
After 2024-03-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-25 · Grant · Acquired 856,671 · Balance 856,671 F1: The shares underlying this option shall vest as follows: 395,387 shares are immediately vested and exercisable, and the remainder shall vest in forty-eight (48) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest as follows: 395,387 shares are immediately vested and exercisable, and the remainder shall vest in forty-eight (48) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 25, 2024 Filed Mar 27, 2024 21:27 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 856,671 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001213900-24-026820 · ownership.xml · derivative · entry 1 Corey Daniel · CIK 0002011547 · Director · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 856,671 Underlying: Common Stock · 856,671 shares Expires 2034-03-24 F1 · derivative.exercise_date: The shares underlying this option shall vest as follows: 395,387 shares are immediately vested and exercisable, and the remainder shall vest in forty-eight (48) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.